[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342042-105":59,"doc-detail-342042-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","clinical-and-genetic-characteristics-of-carriers-of-the-tp53-c541c-t-parg181cys-pathogenic-variant-causing-hereditary-cancer","Clinical and genetic characteristics of carriers of the TP53 c.541C - T, p.Arg181Cys pathogenic variant causing hereditary cancer","","TP53 pathogenic variants cause Li-Fraumeni syndrome (LFS), and some variants produce an attenuated phenotype. This study describes the clinical phenotype and genetic characteristics of carriers of TP53 NM_000546.6 (c.541C>T, p.Arg181Cys) treated at Hadassah Medical Center. From 2005–2022, genetic databases and follow-up of carriers and relatives identified 30 Arab-Muslim carriers, with median diagnosis at 35 years, LFS-typical cancers, and shared founder haplotypes. Exome analysis found no additional known cancer-predisposing variants, and malignancy development showed no unique demographic or exposure factors.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-and-genetic-characteristics-of-carriers-of-the-tp53-c541c-t-parg181cys-pathogenic-variant-causing-hereditary-cancer/342042/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-and-genetic-characteristics-of-carriers-of-the-tp53-c541c-t-parg181cys-pathogenic-variant-causing-hereditary-cancer/342042.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What TP53 variant is studied, and what condition does it cause?","Question",{"text":112,"@type":113},"The study focuses on TP53 c.541C>T (p.Arg181Cys), a pathogenic variant associated with hereditary cancer and an attenuated form of Li-Fraumeni syndrome (LFS).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were TP53 p.Arg181Cys carriers identified and what data were collected?",{"text":117,"@type":113},"Carriers were identified through retrospective review of genetic databases and outreach to carriers and relatives. Clinical and demographic information, lifestyle factors, carcinogenic exposures, and additional blood samples were collected for genetic testing and whole exome sequencing.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the main clinical findings regarding carriers and cancer onset?",{"text":121,"@type":113},"Among 30 Arab-Muslim carriers, the majority met updated Chompret criteria for LFS and the median age of diagnosis was 35 years. A substantial group of healthy carriers was also identified with a median age of 39 years, including some incidental findings.",{"name":123,"@type":110,"acceptedAnswer":124},"What genetic or exposure factors were found to explain malignancy risk?",{"text":125,"@type":113},"Carriers shared a 350 kb haplotype and had limited comorbidities and low BMI. No demographic factors or carcinogenic exposures unique to malignancy were identified, and exome analysis did not reveal other known pathogenic variants in cancer-predisposing genes.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},342042,1790655974,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":41,"preview_page_count":19,"preview_urls":149},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Familial Cancer (2024) 23:531–542  \n[https://doi.org/10.1007/s10689-024-00391-2](https://doi.org/10.1007/s10689-024-00391-2)  \nClinical and genetic characteristics of carriers ofthe TP53 c.541C >T, p.Arg181Cys pathogenic variant causing hereditary cancer in patients of Arab‑Muslim descent  \nJohnathan Arnon1,3 · Aviad Zick1,3 · Myriam Maoz1 · Nada Salaymeh1 · Ahinoam Gugenheim1 ·  \nMazalTov Marouani1,3 · Eden Mor3 · Tamar Hamburger1 · Nagam Saadi3 · Anna Elia3,4 · Gael Ganz2 · Duha Fahham2 · Amichay Meirovitz1,3 · Luna Kadouri1,3 · Vardiella Meiner2,3 · TamarYablonski‑Peretz1,3 · Shiri Shkedi‑Rafid2,3  \nReceived: 23 February 2024 / Accepted: 16 April 2024 / Published online: 14 May 2024 © The Author(s) 2024  \nAbstract  \nTP53 pathogenic variants cause Li-Fraumeni syndrome (LFS), with some variants causing an attenuated phenotype. Herein, we describe the clinical phenotype and genetic characteristics of carriers of NM_000546.6 (TP53): c.541C >T,(p.Arg181Cys) treated at Hadassah Medical Center. We retrospectively examined our genetic databases to identify all carriers of TP53 p.Arg181Cys. We reached out to carriers and their relatives and collected clinical and demographic data, lifestyle factors, carcinogenic exposures as well as additional blood samples for genetic testing and whole exome sequencing. Between 2005 and 2022 a total of 2875 cancer patients underwent genetic testing using genetic panels, whole exome sequencing or targeted TP53 assays. A total of 30 cancer patients, all of Arab-Muslim descent, were found to be carriers of TP53 p.Arg181Cys, the majority from Jerusalem and Hebron, two of which were homozygous for the variant. Carriers were from 24 distinct families of them, 15 families (62.5%) met updated Chompret criteria for LFS. Median age of diagnosis was 35 years-old (range 1–69) with cancers characteristic of LFS (16 Breast cancer; 6 primary CNS tumors; 3 sarcomas) including 4 children with choroid plexus carcinoma, medulloblastoma, or glioblastoma. A total of 21 healthy carriers of TP53 p.Arg181Cys were identified at a median age of 39 years-old (range 2–54)—19 relatives and 2 additional pediatric non-cancer patients, in which the finding was incidental. We report a shared haplotype of 350kb among carriers, limited co-morbidities and low BMI in both cancer patients and healthy carriers. There were no demographic factors or carcinogenic exposures unique to carriers who developed malignancy. Upon exome analysis no other known pathogenic variants in cancer predisposing genes were identified. TP53 p.Arg181Cys is a founder pathogenic variant predominant to the ArabMuslim population in Jerusalem and Hebron, causing attenuated-LFS. We suggest strict surveillance in established carriersand encourage referral to genetic testing for all cancer patients of Arab-Muslim descent in this region with LFS-associated malignancies as well as family members of established carriers.  \nKeywords TP53 · p.Arg181Cys · Arab-Muslim · Li-Fraumeni · Hereditary cancer syndrome  \n\n| Johnathan Arnon and Aviad Zick have joint first authorship. |\n| --- |\n| Tamar Yablonski-Peretz and Shiri Shkedi-Rafid have joint senior authorship. |\n\n* Johnathan Arnon [arnony@hadassah.org.il](arnony@hadassah.org.il)  \nAviad Zick  \n[aviadz@hadassah.org.il](aviadz@hadassah.org.il)  \nShiri Shkedi-Rafid  \n[shirish@hadassah.org.il](shirish@hadassah.org.il)  \n1 Sharett Institute of Oncology, Hadassah University Medical Center, Jerusalem, Israel  \n2 Department of Genetics, Hadassah University Medical Center, Jerusalem, Israel  \n3 Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel  \n4 Department of Pathology, Hadassah University Medical Center, Jerusalem, Israel  \nIntroduction  \nTP53 is a tumor suppressor regulating cell cycle, DNA repair, metabolism and apoptosis in response to DNA or cellular damage. Somatic variants in TP53 are found in over 50% of all human cancers [1] . Germline pathogenic variants in TP53 classically cause Li-Fraumeni syndr","cbCaih0vroLzBb2a","https://ap.wps.com/l/cbCaih0vroLzBb2a","pdf",1150284,12,"English","# Introduction\n## TP53, Li-Fraumeni syndrome, and surveillance rationale\n## Evidence for attenuated and variant-dependent TP53 phenotypes\n## Population context in Israel and study motivation","[{\"question\":\"What TP53 variant is studied, and what condition does it cause?\",\"answer\":\"The study focuses on TP53 c.541C\\u003eT (p.Arg181Cys), a pathogenic variant associated with hereditary cancer and an attenuated form of Li-Fraumeni syndrome (LFS).\"},{\"question\":\"How were TP53 p.Arg181Cys carriers identified and what data were collected?\",\"answer\":\"Carriers were identified through retrospective review of genetic databases and outreach to carriers and relatives. Clinical and demographic information, lifestyle factors, carcinogenic exposures, and additional blood samples were collected for genetic testing and whole exome sequencing.\"},{\"question\":\"What are the main clinical findings regarding carriers and cancer onset?\",\"answer\":\"Among 30 Arab-Muslim carriers, the majority met updated Chompret criteria for LFS and the median age of diagnosis was 35 years. A substantial group of healthy carriers was also identified with a median age of 39 years, including some incidental findings.\"},{\"question\":\"What genetic or exposure factors were found to explain malignancy risk?\",\"answer\":\"Carriers shared a 350 kb haplotype and had limited comorbidities and low BMI. No demographic factors or carcinogenic exposures unique to malignancy were identified, and exome analysis did not reveal other known pathogenic variants in cancer-predisposing genes.\"}]","Clinical and genetic characteristics of carriers of the TP53 c.541C - T, p.Arg181Cys pathogenic variant causing hereditary cancer | PDF",1790044867,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c6292fa71755174643f18528ae5a715.webp",983,1305,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eab070046c6bd83422861faf128154cf.webp",982,1304,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0fa1ae6efefa3f3e2ddbcf04125fce2.webp",981,1303,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6306eadc5b49fe86a7df6dee56f51ffd.webp",980,1301]